



11 September 2018

ASX ANNOUNCEMENT

SOZO® Abstract Presentations at Key Scientific Cardiology Meetings

- *Utilization of Bioimpedance Spectroscopy in Lieu of Invasive Monitoring for Monitoring Fluid Overload*
- *Correlation of Limb Bioimpedance to Echocardiographic Indicators of Congestion in Patients with Heart Failure*

Brisbane, Australia and Carlsbad, CA – ImpediMed Limited (ASX: IPD), a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status using bioimpedance spectroscopy (BIS), announces that two abstracts demonstrating utilisation of its SOZO® device will be presented during poster presentations by A.J. Accardi, M.D. at the upcoming American Heart Congress – CVD, October 5-6, 2018, Los Angeles: *Utilization of Bioimpedance Spectroscopy in Lieu of Invasive Monitoring for Monitoring Fluid Overload* and *Correlation of Limb Bioimpedance to Echocardiographic Indicators of Congestion in Patients with Heart Failure*. These abstracts are expected to be published online in advance of the Congress poster sessions.

This follows on from a successful presentation by Dr. Accardi at the recent World Congress on Heart Disease, sponsored by the International Academy of Cardiology. *Utilization of Bioimpedance Spectroscopy in Lieu of Invasive Monitoring for Monitoring Fluid Overload*, was published online at <https://www.karger.com/Article/Pdf/491714> (page 143.)

Dr. Accardi explains, "There has been a push to identify early markers of impending congestion as well as measures of treatment efficacy as means of providing a cost savings and value in the management of Heart Failure (HF) by preventing admissions. In *Utilization of Bioimpedance Spectroscopy in Lieu of Invasive Monitoring for Monitoring Fluid Overload*, we evaluated the correlation between BIS readings from a SOZO unit and a pulmonary artery diastolic (PAD) device. Findings from the case referenced in the abstract suggest that BIS correlates well with diastolic pulmonary artery pressures and may provide an additional noninvasive tool to detect extracellular fluid excess and impending congestion before hospitalisation. BIS could prove a useful adjunct in the management of HF."

The second abstract, *Correlation of Limb Bioimpedance to Echocardiographic Indicators of Congestion in Patients with Heart Failure*, demonstrates excellent correlations with BIS measurements and IVC size, right atrial pressure and pulmonary artery systolic pressure measurements. This suggests a possible alternative method to detect fluid overload despite the small sample size. Trending a patient's impedance using the SOZO device at

home or the practitioner's office may assist clinicians in providing more accurate, individualised HF care.

Richard Carreon, Managing Director and CEO of ImpediMed, said, "SOZO is the world's first bioimpedance spectroscopy (BIS) device FDA-cleared to monitor a heart failure patient's fluid status in a clinical or at-home setting, SOZO is the most detailed and accurate BIS device available, designed to create a customised plan around individual patients."

He explained that SOZO not only analyses personal data but will also use population health data to compare individual data with others of similar demographics to better understand each patient's health needs.

Richard Carreon
Managing Director & CEO

Media Contact:

Kyahn Williamson, WE Buchan

T: +61 3 9866 4722

E: kwilliamson@buchanwe.com.au

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure and lymphoedema, sold in select markets globally.

For more information, visit www.impedimed.com.